Ticker: BCTX

BriaCell Therapeutics Corp. (NASDAQ: BCTX) recently reported its results for the nine months ended April 30, 2025, showcasing both progress and challenges. The company specializes in developing immunotherapies for cancer treatment and is currently focusing on its pivotal Phase 3 study of Bria-IMT...

BriaCell Therapeutics Corp. (NASDAQ: BCTX) continues to progress in its clinical development of immunotherapies for cancer treatment. The company is mainly focused on its Bria-IMT™ immunotherapy, currently in a pivotal Phase 3 study for metastatic breast cancer, under the U.S. FDA’s Fast Track De...